First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions

Immunotherapy, Ahead of Print.

Source: Immunotherapy - March 9, 2022 Category: Allergy & Immunology Authors: Panpan Jiang Luying Geng Ziyang Mao Qinyang Wang Wenjuan Wang Min Jiao Yu Yao Nanzheng Chen Jia Zhang Kejun Nan Yuan Shen Hui Guo Lili Jiang Source Type: research